📰 **Can Intellia's Gene Editing Therapy Redefine HAE Care After Cutting Attacks By 87% In Phase 3? **

(RTTNews) - Intellia Therapeutics Inc. (NTLA) reported positive Phase 3 results from its global HAELO trial, showing that a single dose of its in vivo CRISPR gene-editing therapy, lonvoguran ziclumeran (lonvo-z), met the primary and all key secondary endpoints in hereditary angio...

🔗 https://www.nasdaq.com/articles/can-intellias-gene-editing-therapy-redefine-hae-care-after-cutting-attacks-87-phase-3

#markets #news